Introducing Paula's Test

LUNG CANCER BLOOD TEST SCREENING

Each year, 160,000 Americans die of lung cancer. Paula Shore was among them. Though she smoked early in life, she had been cigarette-free for over 22 years when she was diagnosed. In fact, she had adopted a healthy lifestyle and undergone the screening tests appropriate for her gender and age. Unfortunately, she still contracted lung cancer, and by the time it was discovered, it showed up as a metastasis of her skin, and there were no treatments available that could save her. Back then, the blood tests available were not able to detect her cancer early when surgery could have saved her life.

Today, there is a simple early detection blood test that can identify lung cancer even when no symptoms are present!

The test developed by 20/20 GeneSystems, Inc. in Rockville MD is known as the PAULA’s Test. The name serves both as an acronym indicating the nature of the test (i.e., Protein Assays Using Lung Cancer Analytes), and to honor one of the Foundation’s namesakes, Paula Shore. Individuals or physicians interested in having the test may obtain additional information at www.paulastest.com.

Founders Commentary

Although lung cancer has not received as much attention as several other cancers, the sad fact is it causes more deaths than the next three most common cancers combined. Smoking is the most common cause. Former smokers remain at increased (but slowly decreasing) risk for several decades after they quit.

In the United States, where many individuals have stopped smoking, the largest group of persons now developing lung cancer are former smokers. We highly recommend the PAULA’s Test yearly for former smokers as well as current smokers. Individuals over the age of 50 with a history of 20 pack-years or more are particularly vulnerable.

Lung cancer may occur as a result of secondhand smoke and pollution, particularly in parts of the world where significant indoor and outdoor pollution exist. In the United States, it has been estimated that 20% of women who develop lung cancer never smoked.

The United States Preventive Services Task Force has recently recommended Spiral CT scanning for certain persons at high risk of lung cancer. There is not yet sufficient data for the task force to issue a statement on the PAULA’s Test. In theory, however, there could be multiple advantages to the PAULA’s Test if preliminary results are confirmed with additional experience. These include reduced exposure to radiation, greater availability of the test, far fewer false-positive results, and potentially earlier detection of lung cancer, which could result in greater survival. It has previously been demonstrated that blood test markers had detected evidence of lung cancer before it was evident on x-ray studies.

https://2020gene.com/products/paulas-test/

https://bloodtestforlungcancer.com/science/

https://bloodtestforlungcancer.com/

SKIN CANCER SCREENING! Catching It Early Every Six Months

Every single hour, someone dies of melanoma. That statistic could be reduced dramatically if the cancer is caught earlier. Early skin cancer does not have the ability to spread through the body! Even though the cells multiply, the cancer can’t invade other layers of skin in the early stages. Only over time do genetic changes occur enabling it to spread. This is precisely why early detection is so vital. Early detection is something Dr. Shore has been advocating for a quarter of a century. At his dermatology practice, he has persuaded high risk patients to come in for check-ups every six months. The results?

 

 

IN OVER 25 YEARS, NOT ONE PERSON IN THE PROGRAM HAS DIED FROM SKIN CANCER OR EVEN HAD A CLOSE CALL:

THE SKIN CHECK PROGRAM – 1992 TO PRESENT

Skin Examinations Performed
1 +
Skin Cancers Detected
1 +
Melanomas Detected
1 +

BUT NO DEATHS DUE TO ANY SKIN CANCERS

*DETAILS OF HIS PROGRAM HAVE BEEN PUBLISHED IN THE JOURNAL OF DRUGS IN DERMATOLOGY: DRUGS-DEVICES-METHODS. 2011;10(3):244-252) AND REPORTED AT MAJOR DERMATOLOGY MEETINGS. THIS ARTICLE (IN PDF) IS PROVIDED WITH COMPLIMENTS BY THE JOURNAL OF DRUGS IN DERMATOLOGY (JDD).